DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Common arthritis drug may boost fight against tough lymphoma
Disease control Not yet recruitingThis study is testing if adding the anti-inflammatory drug celecoxib to the standard chemotherapy regimen (R-CHOP) works better for patients newly diagnosed with an aggressive form of lymphoma called CD5-positive DLBCL. It will involve 60 patients who will be randomly assigned to…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New hope for elderly lymphoma patients: trial tests shorter, targeted treatment
Disease control Not yet recruitingThis study is testing whether adding two newer drugs, mosunetuzumab and polatuzumab vedotin, to a modified chemotherapy regimen can better treat aggressive lymphoma in older adults. The goal is to see if this combination improves the chance of a complete response and allows some …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New combo aims to boost powerful cancer treatment
Disease control Not yet recruitingThis early-stage study is testing if a combination of targeted radiation and an oral antibiotic is safe and feasible to give before a patient's own immune cells are engineered to fight their cancer (CAR-T therapy). It is for adults with aggressive B-cell lymphomas that have come …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Double-Punch T-Cells take aim at stubborn blood cancers
Disease control Not yet recruitingThis early study is testing a new type of cell therapy for patients whose B-cell lymphoma has come back or hasn't responded to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to attack two specific targets on the cancer cells (CD19 and CD…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for lymphoma patients: experimental drug combo enters testing
Disease control Not yet recruitingThis study is testing whether adding a new drug called lisatoclax to standard lymphoma treatments is safe and effective for people with untreated diffuse large B-cell lymphoma. Researchers will enroll 122 patients to receive either lisatoclax plus R-CHOP or lisatoclax plus Pola-R…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Pioneering cancer treatment trial launches in colombia
Disease control Not yet recruitingThis study has two main goals. First, it aims to set up the systems needed to make and deliver a type of personalized cell therapy called CAR-T in Colombia. Second, it will test the safety of this specific CAR-T therapy in a small group of adults with advanced blood cancers that …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
Researchers track what happens when a key lymphoma drug stops working
Knowledge-focused Not yet recruitingThis study aims to understand what happens to patients with diffuse large B-cell lymphoma (DLBCL) after their cancer progresses despite treatment with a drug called polatuzumab vedotin. Researchers will look back at medical records and follow patients forward to see what treatmen…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Scientists track brain fog in cancer patients after revolutionary CAR-T treatment
Knowledge-focused Not yet recruitingThis study aims to understand how CAR-T cell therapy affects memory, thinking skills, and quality of life in adults with certain aggressive lymphomas. Researchers will follow 100 patients in Italy for two years, starting assessments before treatment and checking in at 6, 12, and …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC